[1]喻 晶,李运雷,刘晓翌.非小细胞肺癌患者不同类型样本中表皮生长因子受体基因突变的差异研究[J].现代检验医学杂志,2018,33(04):31-33.[doi:10.3969/j.issn.1671-7414.2018.04.008]
　YU Jing,LI Yun-lei,LIU Xiao-yi.Detection of Epidermal Growth Factor Receptor Gene Mutation in Different Sample Types of 238 Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):31-33.[doi:10.3969/j.issn.1671-7414.2018.04.008]
点击复制

非小细胞肺癌患者不同类型样本中表皮生长因子受体基因突变的差异研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年04期
页码:
31-33
栏目:
论著
出版日期:
2018-08-30

文章信息/Info

Title:
Detection of Epidermal Growth Factor Receptor Gene Mutation in Different Sample Types of 238 Patients with Non-small Cell Lung Cancer
文章编号:
1671-7414(2018)04-031-03
作者:
喻 晶; 李运雷; 刘晓翌
北京大学深圳医院检验科,广东深圳 518036
Author(s):
YU Jing; LI Yun-lei; LIU Xiao-yi
Department of Laboratory Medicine, Beijing University Shenzhen Hospital,Guangdong Shenzhen 518036,China
关键词:
表皮生长因子受体(EGFR)基因突变;  不同类型样本;  非小细胞肺癌;  扩增阻碍突变系统(ARMS)
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.04.008
文献标志码:
A
摘要:
目的 检测238例非小细胞肺癌(NSCLC)患者不同类型样本中表皮生长因子受体(EGFR)基因的突变情况,探讨不同类型样本在EGFR基因突变中的应用价值。方法 采用扩增阻碍突变系统(ARMS)检测238例NSCLC中EGFR基因18～21外显子的突变情况,探讨不同样本类型、不同性别、不同年龄、不同病理分型和不同临床分期的EGFR突变频率的差异及临床意义。结果 238例NSCLC患者EGFR总的突变率为44.5%(106/238),其中组织、血浆和胸腔积液样本分别为105例,115例和18例,其突变率分别为52.4%(55/105),34.8%(40/115)和61.1%(11/18),与组织样本相比,血浆样本的EGFR突变检出率明显低于组织样本,差异具有统计学意义(χ2=6.93,P<0.05),但组织与胸腔积液样本相比其检出率差异无统计学意义(χ2=0.471,P>0.05)。女性NSCLC患者的EGFR突变的检出率明显高于男性患者,差异有统计学意义(55.3% vs 36.3%,χ2=8.58,P<0.01)。>65岁患者与≤65岁患者的突变检出率差异无统计学意义(44.4% vs 44.6%,χ2=0,P>0.05)。肺腺癌的EGFR突变检出率明显高于其他类型的NSCLC,差异有统计学意义(47.7% vs 29.3%,χ2=4.68,P<0.05)。临床I～II期患者的EGFR突变检出率与III～IV期的相比差异无统计学意义(35.0% vs 45.7%,χ2=0.79,P>0.05)。结论 组织样本EGFR基因突变的检出率与胸腔积液样本相比无统计学差异,但明显高于血浆样本,提示临床选择送检的样本类型时,可优先选择组织和胸腔积液样本。EGFR基因突变的检出率与性别和肿瘤的病理类型相关。
Abstract:
Abstract:Objective To detect the epidermal growth factorreceptor(EGFR)mutation in different types of samples of 238 patients with non-small cell lung cancer(NSCLC),and explore the clinical application valueof the EGFR gene mutation in different types of samples.Methods Mutations in the exons 18-21 of EGFR gene in 238 patients with non-small cell lung cancer were detected by amplification refractory mutation system(ARMS),to investigate the frequency and clinical significance of EGFR mutation in different sample types,genders,ages,pathological types,and clinical stages.Results The total mutation rate of EGFR was 44.5%(106/238)in 238 patients with NSCLC.The number of tissue,plasma and pleural effusion samples were 105,115 and 18,and the mutation rate was 52.4%(55/105),34.8%(40/115),61.1%(11/18)respectively.Compared with tissue sample,the mutation rate of plasma samples was significantly lower than that of tissue samples,the difference was statistically significant(χ2=6.93,P<0.05),butthere was no statistical difference of mutation rate in pleural effusion samples compared with tissue samples(χ2=0.471,P>0.05).The EGFR mutations rate in female NSCLC patients was dramatically higher than that of male patients(55.3% vs 36.3%,χ2=8.58,P<0.01).No statistical difference of the mutation rate was found between patients >65 years old and ≤65 years old(44.4%vs 44.6%,χ2=0,P>0.05).The EGFR mutation rate in patients with lungadenocarcinoma was significantly higher than that of patients with other types of NSCLC(47.7% vs 29.3%,χ2=4.68,P<0.05).There was no statisticaldifference in the EGFR mutation rate between patients in clinical stage I-II and in stage III-IV(35.0% vs 45.7%,χ2=0.79,P>0.05).Conclusion The EGFR mutations rate in tissue samples had no significantdifference from that of pleural effusion samples,but it was significantly higher than that of plasma samples.This suggests that tissue and pleural effusionsamples could be the first choice for the clinical selection to be submitted forEGRF mutation detection.The EGFR mutation rate is related to gender and the pathological type of the lung tumor.

参考文献/References:

[1] Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA:A Cancer Journal for Clinicians,2015,65(1):5-29.
[2] Reck M,Heigener DF,Mok T,et al.Management of non-small-cell lung cancer: recent developments[J].Lancet,2013,382(9893):709-719.
[3] 周瑞芳,卢仁泉.EGFR基因突变检测的临床应用[J].现代检验医学杂志,2013,28(3):72-74. Zhou RF,Lu RQ.Clinical application of detecting E GFR mutations[J].Journal of Modern Laboratory Medicine,2013,28(3):72-74.
[4] Sharma SV,Bell DW,Settleman J,et al.Epidermal growth factor receptormutations in lung cancer[ J].Nat Rev Cancer,2007,7(3):169-181.
[5] 禹 乐,朱启淦,杨立民,等.胸水细胞块EGFR基因突变检测在非小细胞肺癌中的临床意义[J].山西医科大学学报,2017,48(5):462-466. Yu L,Zhu QG,Yang LM,et al.Clinical significance of EGFR gene mutation in pleural effusion cell blocks in non-small cell lung cancer[J].Journal of Shanxi Medical University,2017,48(5):462-466.
[6] Goto K,Ichinose Y,Ohe Y,et al.Epidermal growth factor receptor mutation status in circulating free DNA in serum:from IPASS,a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J].J Thorac Oncol,2012,7(1):115-121.
[7] Gao B,Sun Y,Zhang J,et al.Spectrum of LKBl,EGFR,and KRAS mutationsin Chinese lung adenocarcinomas[J].J Thorae Oncol,2010,5(8):1130-1135.

备注/Memo

备注/Memo:
作者简介:喻 晶(1967-),女,医学硕士,主任技师,主要从事临床分子生物学研究,E-mail:jing_yu2004@aliyun.com。
更新日期/Last Update: 2018-08-16